
PONOS CLINIC · CLINICAL CASE · CRANIOFACIAL PAIN
Neuromodulation of the left sphenopalatine ganglion: a case of neuropathic facial pain
The aim was clear: to control the neuropathic component of facial pain. Following a technically very difficult pulsed radiofrequency procedure on the left sphenopalatine ganglion, this component resolved and remained in remission at the October 2026 follow-up.
← PONOS clinical cases · De-identified clinical case
A precisely defined clinical target
This patient had both a left mandibular bone lesion and facial pain with neuropathic features. Treatment of the sphenopalatine ganglion had a shared and specific goal: to control the facial neuropathic component. It was not proposed as treatment for the bone lesion.
This distinction was part of the original indication. It allows the outcome to be assessed against the problem being treated: resolution of neuropathic pain, while assessment of the mandibular condition continued.
Persistent facial pain with sensory changes
The patient, a woman in her forties, had experienced left-sided facial symptoms for approximately one year. The pain assessment described reduced pinprick sensation, altered tactile sensation, paraesthesia and dysaesthesia in the trigeminal distribution, with burning predominantly in the mandibular region. Ipsilateral occipital symptoms also coexisted and were considered separately.
Several investigations and treatments had already been undertaken. According to the pain records, duloxetine and pregabalin had not provided useful, sustained benefit. A previous peripheral pulsed radiofrequency treatment had produced reported relief for approximately twenty days. Botulinum toxin and zoledronate had also been tried, without lasting control of the described symptoms.
Carbamazepine had provided partial benefit, which became more marked after an increase to 300 mg three times daily. However, the April 2026 preoperative note documented persistence of the painful component for which the sphenopalatine procedure was proposed.
The maxillofacial and neurosurgical assessments recorded in the history had not identified a surgical indication at the time. Pain is not automatically attributed to an imaging finding or possible neurovascular contact.
The bone lesion and the limits of histological diagnosis
Facial CT described osteosclerotic remodelling of the left mandibular body and angle, with a ground-glass appearance, favouring fibrous dysplasia as the leading hypothesis. The 2025 follow-up described the findings as substantially unchanged, within the limits of the available comparison, with intact cortices.
The mandibular biopsy report described compact cortical bone associated with areas of fibrosis. Its conclusion was non-diagnostic, although not inconsistent with the clinical hypothesis of fibrous dysplasia. This limitation is retained in the case presentation: compatibility is not treated as definitive histological confirmation.
Bone scintigraphy documented an intense area of remodelling in the left mandibular body, without other skeletal foci of similar significance. Specialist and bone-metabolism assessment continued alongside treatment of the neuropathic component.
Neuromodulation of the left sphenopalatine ganglion: an extremely technically difficult procedure
On 22 April 2026, the patient underwent neuromodulation with pulsed radiofrequency of the left sphenopalatine ganglion. Dr Evangelos Panagiotakos describes an extremely technically difficult procedure. The fluoroscopic sequence documents several projections and successive checks of instrument position; the selected images retain their original order.
The images are not used to infer the precise moment at which the target was reached or pulsed radiofrequency activated. Position selection and treatment details are reported from the documentation and the operator’s confirmation.
| Target and side | Left sphenopalatine ganglion |
|---|---|
| Technique | Pulsed radiofrequency neuromodulation |
| Generator | Cosman G4, as recorded in the discharge letter |
| Parameters | 10 minutes · 42 °C · 100 V |
| Needle | Blunt-type needle with a non-cutting pencil-point tip, as described by the operator |
The discharge diagnosis was “trigeminal autonomic cephalalgia”. This presentation focuses on the facial neuropathic component described in the clinical history and the pain-treatment goal confirmed by the operator.
A 46-second montage of 23 selected static fluoroscopic images, changing every 2 seconds with a brief crossfade. The first 11 acquisitions, in which no needle was visible, have been omitted; source images 12–34 retain their original order. Crossfades are editorial effects and do not reconstruct anatomical movement. Captions report the operator’s details. Times refer to image acquisition, not a continuous recording. The original video captions are in Italian.
The outcome: remission of the facial neuropathic component
The treatment goal for neuropathic facial pain was achieved. The operator’s clinical update of 16 October 2026 reports resolution of this component after pulsed radiofrequency, with remission maintained up to that date.
| Time point | Available information |
|---|---|
| April 2026, before the procedure | Benefit from carbamazepine, with persistence of the component for which sphenopalatine ganglion treatment was indicated. |
| 22 April 2026 | Neuromodulation of the left sphenopalatine ganglion. |
| 23 April 2026 | Discharged with NRS 0, Aldrete score 10, a favourable perioperative course and no reported new neurological deficits. |
| July 2026 | The endocrinology report documents benefit after the procedure, reduction of carbamazepine to 200 mg once daily and good control of left-sided facial pain. It also records other interventions and concurrent symptoms. |
| October 2026 | The operator confirms sustained remission of neuropathic facial pain and reports focal somatic pain at the mandibular lesion as a separate problem under investigation. |
NRS 0 was recorded at discharge. Subsequent follow-up is clinical, without available standardised scores. Medication reduction was documented in July; complete discontinuation was not reported.
The July report also documents subsequent local treatment for a cheek symptom and other concurrent pain. These elements are kept separate, and not every later change is attributed to pulsed radiofrequency.
The current focal somatic pain is a separate problem
More recently, focal somatic pain has reappeared at the lesion site. According to the operator’s update, this is not a recurrence of the treated neuropathic facial pain, which remains in remission. The patient is undergoing further investigations.
Results of the new investigations are not available in this presentation. No conclusions are therefore drawn about progression of the lesion or the specific cause of the focal pain. Control of the neuropathic component and reassessment of the local condition are distinct clinical goals.
What this case illustrates
The value of this case lies in defining the goal: recognising a facial neuropathic component and treating it selectively, while a coexisting bone condition continued to require its own specialist assessment.
The technical difficulty makes documentation of the approach and positioning checks particularly relevant. This individual course shows a favourable and sustained outcome for the chosen clinical target. It does not predict outcomes in other people or establish an indication for every form of mandibular pain.
Further reading: sphenopalatine ganglion and the treatment pathway · how sphenopalatine ganglion neuromodulation is performed · other clinical cases.
Case reconstructed from the supplied clinical documentation and Dr Evangelos Panagiotakos’s update of 16 October 2026. Patient identifiers have been omitted. Full clinical reports are not attached to this presentation.